Sarah C Gilbert

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. pmc Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1
    Tamara K Berthoud
    The Jenner Institute, Oxford University, Oxford, United Kingdom
    Clin Infect Dis 52:1-7. 2011
  2. doi request reprint Advances in the development of universal influenza vaccines
    Sarah C Gilbert
    Jenner Institute, University of Oxford, Oxford, UK
    Influenza Other Respir Viruses 7:750-8. 2013
  3. ncbi request reprint Clinical development of Modified Vaccinia virus Ankara vaccines
    Sarah C Gilbert
    Jenner Institute, University of Oxford, ORCRB, OX3 7DQ, UK
    Vaccine 31:4241-6. 2013
  4. pmc T-cell-inducing vaccines - what's the future
    Sarah C Gilbert
    Jenner Institute, University of Oxford, UK
    Immunology 135:19-26. 2012
  5. pmc Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
    Daniel P Webster
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    Proc Natl Acad Sci U S A 102:4836-41. 2005
  6. doi request reprint Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
    Arturo Reyes-Sandoval
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Eur J Immunol 38:732-41. 2008
  7. ncbi request reprint Prime-boost vectored malaria vaccines: progress and prospects
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Oxford, UK
    Hum Vaccin 6:78-83. 2010
  8. pmc Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein
    Michael Walther
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, United Kingdom
    Infect Immun 74:2706-16. 2006
  9. pmc Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
    Mol Ther 19:2269-76. 2011
  10. pmc The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment
    Anna L Goodman
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
    Sci Rep 3:1706. 2013

Detail Information

Publications66

  1. pmc Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1
    Tamara K Berthoud
    The Jenner Institute, Oxford University, Oxford, United Kingdom
    Clin Infect Dis 52:1-7. 2011
    ..A vaccine providing protective immunity to the highly conserved internal antigens could provide longer-lasting protection against multiple influenza subtypes...
  2. doi request reprint Advances in the development of universal influenza vaccines
    Sarah C Gilbert
    Jenner Institute, University of Oxford, Oxford, UK
    Influenza Other Respir Viruses 7:750-8. 2013
    ..Several of these have now been taken into clinical development, and this review discusses the progress that has been made, as well as considering the requirements for licensing these new vaccines and how they might be used in the future...
  3. ncbi request reprint Clinical development of Modified Vaccinia virus Ankara vaccines
    Sarah C Gilbert
    Jenner Institute, University of Oxford, ORCRB, OX3 7DQ, UK
    Vaccine 31:4241-6. 2013
    ..The safety of MVA is now well documented, immunogenicity is influenced by the dose and vaccination regimen, and information on the efficacy of MVA-vectored vaccines is now beginning to accumulate...
  4. pmc T-cell-inducing vaccines - what's the future
    Sarah C Gilbert
    Jenner Institute, University of Oxford, UK
    Immunology 135:19-26. 2012
    ....
  5. pmc Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
    Daniel P Webster
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford OX3 7LJ, UK
    Proc Natl Acad Sci U S A 102:4836-41. 2005
    ....
  6. doi request reprint Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
    Arturo Reyes-Sandoval
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Eur J Immunol 38:732-41. 2008
    ..Our data suggest that T(EM) cells are important as a first line of defense against fast-replicating pathogens such as murine Plasmodium and demonstrate the potential of replication-defective SAd as future malaria vaccines for humans...
  7. ncbi request reprint Prime-boost vectored malaria vaccines: progress and prospects
    Adrian V S Hill
    The Jenner Institute, University of Oxford, Oxford, UK
    Hum Vaccin 6:78-83. 2010
    ..These viral vectors now provide a major option for inclusion in a high efficacy multi-stage malaria vaccine that should achieve deployable levels of efficacy in endemic settings...
  8. pmc Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein
    Michael Walther
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, United Kingdom
    Infect Immun 74:2706-16. 2006
    ..Vaccines containing this antigen proved safe and induced modest immune responses but showed no evidence of efficacy in a sporozoite challenge...
  9. pmc Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
    Mol Ther 19:2269-76. 2011
    ..Further studies are required to assess whether this strategy can achieve protective efficacy against blood-stage malaria infection...
  10. pmc The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment
    Anna L Goodman
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK
    Sci Rep 3:1706. 2013
    ..An improved understanding of the mechanisms responsible for protection, or failure of protection, against P. berghei merozoites could guide the development of an efficacious vaccine against P. falciparum...
  11. ncbi request reprint Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers
    Jenni M Vuola
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, UK
    J Immunol 174:449-55. 2005
    ..This difference may be of importance for the protective efficacy of these vaccination approaches against various diseases...
  12. ncbi request reprint Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria
    Sheila M Keating
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, Churchill Hospital, Oxford, United Kingdom
    J Immunol 175:5675-80. 2005
    ..This cultured assay identifies long-lasting protective T cell responses and therefore offers an attractive option for assessments of vaccine immunogenicity...
  13. pmc Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1
    Sumi Biswas
    The Jenner Institute, University of Oxford, Oxford, Oxfordshire, United Kingdom
    PLoS ONE 6:e20977. 2011
    ..Here we describe the pre-clinical development and optimization of recombinant human and simian adenoviral (AdHu5 and ChAd63) and orthopoxviral (MVA) vectors encoding transgene inserts for Plasmodium falciparum AMA1 (PfAMA1)...
  14. pmc Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
    Cell Host Microbe 5:95-105. 2009
    ..Multistage immunity against malaria can thus be achieved by using viral vectors recombinant for MSP-1...
  15. ncbi request reprint A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS
    Susanna J Dunachie
    Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Vaccine 24:2850-9. 2006
    ..Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3-77.7%), with one subject remaining fully protected on rechallenge at 5 months...
  16. pmc Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates
    Alexandra J Spencer
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e33555. 2012
    ..This report demonstrates that antigen multimerization using IMX313 is a simple and effective cross-species method to improve vaccine immunogenicity with potentially broad applicability...
  17. ncbi request reprint Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity
    Claire L Hutchings
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Immunol 175:599-606. 2005
    ....
  18. doi request reprint Effective induction of high-titer antibodies by viral vector vaccines
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Nat Med 14:819-21. 2008
    ..Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro...
  19. pmc Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine
    Timothy J Powell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    PLoS ONE 8:e62778. 2013
    ..BCL2 expression was lower in vaccinated volunteers. These data indicate that antigen specific T cells are a useful additional measure for use in human vaccination or immunization studies...
  20. ncbi request reprint Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Vaccine 24:4554-61. 2006
    ..In this review we summarise the safety, immunogenicity and efficacy results from these malaria and tuberculosis vaccine clinical trials...
  21. pmc Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses
    Arturo Reyes-Sandoval
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom
    Infect Immun 78:145-53. 2010
    ....
  22. pmc A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses
    Eric Prieur
    Weatherall Institute of Molecular Medicine and Cellular Immunology, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
    Proc Natl Acad Sci U S A 101:290-5. 2004
    ..The use of polyprotein constructs in nonreplicating poxviruses should broaden the target antigen range of vaccine-induced immunity and increase the number of potential epitopes available for immunogenetically diverse human populations...
  23. ncbi request reprint Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus
    Richard J Anderson
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    J Immunol 172:3094-100. 2004
    ..berghei and was more immunogenic and protective than DNA/MVA prime/boost immunization. However, further improvement was not achieved by sequential (triple) immunization with a DNA vaccine, FP9, and MVA...
  24. pmc Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom
    PLoS ONE 7:e31208. 2012
    ..falciparum. The development of a vaccine that could induce both cell-mediated and humoral immune responses would enable important proof-of-concept efficacy studies to be undertaken to address this question...
  25. pmc A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine
    David W Porter
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK
    Vaccine 29:7514-22. 2011
    ..There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene...
  26. pmc Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1
    Teresa Lambe
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    Sci Rep 3:1443. 2013
    ..These data may be of relevance for the design of optimal immunization regimens for human influenza vaccines, especially for influenza-naïve infants...
  27. pmc Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection
    Alexander D Douglas
    Jenner Institute, University of Oxford, UK
    J Infect Dis 208:340-5. 2013
    ..We find that the parameters estimated by these models are closely correlated, and their predictive accuracy for omitted data points was similar. We propose that future studies include the linear model...
  28. pmc ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans
    Susanne H Sheehy
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Churchill Hospital, Oxford, UK
    Mol Ther 20:2355-68. 2012
    ..These data call into question the utility of T cell-inducing blood-stage malaria vaccines and suggest that the focus should remain on high-titer antibody induction against susceptible antigen targets...
  29. pmc Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection
    Sumi Biswas
    Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
    J Immunol 188:5041-53. 2012
    ....
  30. ncbi request reprint Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites
    Philip Bejon
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
    J Infect Dis 191:619-26. 2005
    ..Forty-eight-hour growth rates in blood from control subjects were not different from those in blood from any vaccination group (mean, 14.4-fold [95% confidence interval, 11-19-fold])...
  31. pmc Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference
    Emily K Forbes
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    J Immunol 187:3738-50. 2011
    ..These data have important implications for the development of a multistage or multicomponent viral vectored malaria vaccine for use in humans...
  32. doi request reprint Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines
    Simon J Draper
    Jenner Institute, University of Oxford, Oxford, OX3 7DQ, United Kingdom
    J Immunol 185:7583-95. 2010
    ..These data encourage the further clinical development and coadministration of protein and viral vector vaccine platforms in an attempt to induce broad cellular and humoral immune responses against blood-stage malaria Ags in humans...
  33. pmc The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus
    Simone C de Cassan
    The Jenner Institute, University of Oxford, Headington, Oxford OX3 7DQ, United Kingdom
    J Immunol 187:2602-16. 2011
    ....
  34. ncbi request reprint Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance
    Anne C Moore
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, United Kingdom
    J Immunol 175:7264-73. 2005
    ..Vaccine strategies incorporating anti-CD25 lead to improved protection against pre-erythrocytic malaria challenge. These data underpin new strategies for the design and development of more efficacious vaccines in clinical settings...
  35. pmc Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector
    Geraldine A O'Hara
    Centre for Clinical Vaccinology and Tropical Medicine and the Jenner Institute Laboratories, University of Oxford, UK
    J Infect Dis 205:772-81. 2012
    ..Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses...
  36. pmc Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus
    Amy C Boyd
    The Jenner Institute, Oxford University, Oxford, UK
    Vaccine 31:670-5. 2013
    ....
  37. pmc Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)
    Matthew G Cottingham
    Wellcome Trust Centre for Human Genetics and The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 3:e1638. 2008
    ..Here we demonstrate in proof-of-concept experiments that MVA-BAC recombineering is a viable route to more rapid and efficient generation of new candidate mutant and recombinant vaccines based on a clinically deployable viral vector...
  38. pmc Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1
    Alexander D Douglas
    Jenner Institute, Oxford University, Oxford, UK
    Vaccine 28:7167-78. 2010
    ....
  39. pmc Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial
    Rosalind Rowland
    Jenner Institute University of Oxford, Oxford, UK
    Hum Vaccin Immunother 9:50-62. 2013
    ..We hypothesize that FP85A induced anti-FP9 IgG antibodies with cross-reactivity for MVA85A, which may have mediated inhibition of the immune response to subsequent MVA85A. ClinicalTrials.gov identification number: NCT00653770...
  40. ncbi request reprint Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials
    Laura Andrews
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Am J Trop Med Hyg 73:191-8. 2005
    ..This PCR method has so far been used to follow 137 vaccinee and control volunteers in Phase IIa trials in Oxford and on 220 volunteer samples during a Phase IIb field trial in The Gambia...
  41. ncbi request reprint Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence
    Caroline L Smith
    Tumour Immunology Unit, Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, Oxford University, Oxford, OX3 9DS, UK
    Int J Cancer 113:259-66. 2005
    ....
  42. pmc Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909
    Christopher J A Duncan
    Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e22271. 2011
    ..Here we report the first study to examine the relationship between in vivo Plasmodium falciparum growth rates and in vitro GIA in humans experimentally infected with blood-stage malaria...
  43. pmc Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans
    Patrick J Lillie
    Jenner Institute, University of Oxford, UK
    Clin Infect Dis 55:19-25. 2012
    ..Following a phase 1 clinical study that demonstrated vaccine safety and immunogenicity, a phase 2a vaccination and influenza challenge study has been conducted in healthy adult volunteers...
  44. pmc A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years
    Richard D Antrobus
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e48322. 2012
    ..We assessed the safety and immunogenicity of MVA-NP+M1, a viral-vectored influenza vaccine designed to boost memory T cell responses, in a group of older adults...
  45. pmc Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial
    Fiona M Thompson
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, United Kingdom
    PLoS ONE 3:e1493. 2008
    ..This trial was the first to combine two existing vaccination strategies to produce a vaccine that induces immune responses to both the pre-erythrocytic and blood stages of the P. falciparum life cycle...
  46. ncbi request reprint Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction
    Shahriar Behboudi
    Nuffield Department of Clinical Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DU, UK
    Vaccine 22:4326-31. 2004
    ..These data indicate that despite the ability of poxviruses to impair DC maturation in vivo, the important ability of MVA to boost CD8 T-cell response in vivo is mediated at the level of the infected dendritic cells...
  47. doi request reprint Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines
    Karen Colbjørn Larsen
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, United Kingdom
    Vaccine 27:5589-98. 2009
    ..These results indicate that optimal immunogenicity may require activation of distinct innate immune signalling pathways. Thus this strategy offers a novel route to the discovery of a new generation of adjuvants...
  48. pmc Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density
    Philip Bejon
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford, OX3 7LJ, UK
    Malar J 5:104. 2006
    ..Thick blood films are routinely used to diagnose Plasmodium falciparum malaria. Here, they were used to diagnose volunteers exposed to experimental malaria challenge...
  49. ncbi request reprint Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK
    Nat Med 10:1240-4. 2004
    ..Boosting vaccinations with MVA85A could offer a practical and efficient strategy for enhancing and prolonging antimycobacterial immunity in tuberculosis-endemic areas...
  50. ncbi request reprint Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection
    Michael Walther
    Center for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
    Immunity 23:287-96. 2005
    ..P. falciparum-mediated induction of regulatory T cells may represent a parasite-specific virulence factor...
  51. ncbi request reprint Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes
    Michael Walther
    Center for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, Churchill Hospital, Oxford, United Kingdom
    J Immunol 177:5736-45. 2006
    ..Furthermore, the in vitro observations on cytokine kinetics presented here, suggest that intact schizont-stage infected RBC can trigger innate responses before rupture of the infected RBC...
  52. pmc Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies
    Patrick J Lillie
    Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK
    Travel Med Infect Dis 10:192-6. 2012
    ..These data support incorporating travel history into pandemic algorithms...
  53. ncbi request reprint Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome
    Matthew G Cottingham
    The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK
    J Virol Methods 168:233-6. 2010
    ..These methods greatly facilitate and accelerate production of recombinant MVA, including markerless constructs...
  54. doi request reprint Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine
    Caitlin E Mullarkey
    Jenner Institute, Old Road Campus Research Building, Oxford, UK
    Eur J Immunol 43:1940-52. 2013
    ..The simultaneous induction of T cells and Ab responses has the potential to improve seasonal vaccine performance and could be employed in pandemic situations. ..
  55. ncbi request reprint Utilizing poxviral vectored vaccines for antibody induction-progress and prospects
    Simon J Draper
    The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK
    Vaccine 31:4223-30. 2013
    ....
  56. ncbi request reprint Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors
    Matthew G Cottingham
    The Jenner Institute, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, UK
    Biotechnol Bioeng 109:719-28. 2012
    ..These results have important implications for basic and pre-clinical studies using adenoviral vectors and for derivation of adenoviral vector products destined for large-scale amplification during biomanufacture...
  57. pmc A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity
    Matthew D J Dicks
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e40385. 2012
    ..These findings support the continued development of new chimpanzee adenovirus vectors, including ChAdY25, for clinical use...
  58. pmc Incidental diagnosis in healthy clinical trial subjects
    Christopher J A Duncan
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Drive, OX3 7LJ, United Kingdom
    Clin Transl Sci 5:348-50. 2012
    ..02 χ(2) for trend) but not females (p= 0.82). These data will assist those planning and conducting phase I/II vaccine trials in healthy volunteers, and importantly should strengthen the informed consent of future trial participants...
  59. ncbi request reprint Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
    Samuel J McConkey
    Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, UK
    Nat Med 9:729-35. 2003
    ..Such heterologous prime-boost immunization approaches may provide a basis for preventative and therapeutic vaccination in humans...
  60. ncbi request reprint Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice
    George M Warimwe
    The Jenner Institute, University of Oxford, Oxford, UK
    Virol J 10:349. 2013
    ....
  61. ncbi request reprint Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens
    Richard D Antrobus
    The Jenner Institute, University of Oxford, Oxford, UK
    Mol Ther 22:668-74. 2014
    ..We demonstrate ChAdOx1 NP+M1 to be safe and immunogenic. ChAdOx1 is a promising vaccine vector that could be used to deliver vaccine antigens where strong cellular immune responses are required for protection. ..
  62. ncbi request reprint Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses
    Richard D Antrobus
    The Jenner Institute, University of Oxford, Oxford, UK
    Mol Ther 22:233-8. 2014
    ....
  63. pmc Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA
    Toritse Orubu
    The Jenner Institute, University of Oxford, Oxford, United Kingdom
    PLoS ONE 7:e40167. 2012
    ....
  64. pmc Dual neonate vaccine platform against HIV-1 and M. tuberculosis
    Richard Hopkins
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    PLoS ONE 6:e20067. 2011
    ..tuberculosis infant vaccine platform is established. Induction of immune responses against these pathogens soon after birth is highly desirable and may provide a basis for lifetime protection maintained by boosts later in life...
  65. ncbi request reprint Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes
    Sarah C Gilbert
    Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, OX3 7BN, Oxford, UK
    Vaccine 20:1039-45. 2002
    ..This study identifies recombinant replication-defective adenovirus as an alternative to recombinant replication-defective poxviruses as boosting agents for the induction of strong protective CD8(+) T cell responses...
  66. ncbi request reprint T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine
    Teresa Lambe
    Jenner Institute, Old Road Campus Research Building, Oxford, UK
    Pediatr Infect Dis J 31:e86-91. 2012
    ..We investigate here the influenza-specific T-cell response, in children, 1 year after pandemic H1N1 vaccination and the ability to boost the T-cell response with trivalent-inactivated influenza immunization...